Gilead dangles $105M in quick cash to sign Scholar Rock to a discovery deal for its growing NASH pipeline
At last count Gilead $GILD had 3 clinical stage programs for NASH in the pipeline, topped by their Phase III work on selonsertib.
But that’s not enough.
Today the big biotech — which is getting a brain transplant in the executive suite as Roche’s Daniel O’Day heads for the helm — added a discovery program with Scholar Rock $SRRK on a slate of TGFβ inhibitors for fibrotic diseases, beefing up a portfolio of drugs that encompass NASH and diabetic kidney disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.